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Introduction 
 
Microtubules, a component of the cytoskeleton in eukaryotes, have a 
cylindrical structure that consists of polymerized α/β-tubulin. Microtubules are involved 
in spindle formation in mitosis, cellular signaling, cell motility and the determination of 
organelle positions.  
In mitosis, there is a key regulation machinery, mitotic/spindle checkpoint 
which regulate the entry to anaphase. In this checkpoint system, the kinetochore in the 
prophase/early prometaphase recruits several mitotic checkpoint components, (e. g. 
BUBR1, MAD2, CEMPE and more), which inhibit the CDC20-dependent recognition 
of cyclin B and securin by Anaphase promoting complex/Cyclosome (APC/C). When 
the microtubules are captured and tension is detected at the kinetochore, the mitotic 
checkpoint is satisfied, and the cell cycle progresses with entries into anaphase by the 
degradation of cyclin B and securin by APC/C.1 But when even one chromosome is not 
properly captured by microtubules, the mitotic checkpoint is activated to keep cells 
from aneuploidy and apoptotic cell death. Because cancer cells have abnormal mitotic 
checkpoints, miss segregation and apoptosis are easily induced in cancer cells.2 
Microtubule polymerization inhibitors (e.g., vinca alkaloids) and microtubule 
  
stabilizers (e.g., taxane) have been used for cancer chemotherapy. These microtubule 
inhibitors prevent spindle formation and arrest cell cycle progression at M-phase by 
activating the mitotic/spindle checkpoint, subsequently inducing cell death in cancer.3 
However, these microtubule inhibitors can also cause some severe side effects, 
including peripheral neuropathy. It is thought that this side effect occurs due to the 
extreme effects on the microtubules of non-proliferative cells, which are in interphase.3 
Against this background, microtubule dynamics have been recognized as an 
attractive target for cancer chemotherapy that may help avoid the side effects of 
microtubule destabilizers and stabilizers. Microtubule plus ends repeatedly grow and 
then shorten, and this phenomenon is called “microtubule dynamics”. These dynamics 
are regulated by GTP/GDP on β-tubulin.4 In α-tubulin, GTP is not hydrolyzed and it 
supports the structure of tubulin heterodimer. In contrast, GTP bound to β-tubulin is 
hydrolyzed, and the hydrolysis reaction changes the conformation of the α/β-tubulin 
heterodimer, and subsequently the de-polymerization of microtubule occurs (this 
transition forward to de-polymerization is called a “catastrophe”). Microtubule 
dynamics consist of three phases, growing, shortening, and pause (neither growing nor 
shortening) and two transitions: catastrophe (transition from growing or pause to 
shortening) and rescue (transition from shortening to growing or pause).  
  
For example, the microtubule dynamics inhibitor, eribulin, a synthetic analog of 
halicondrine B,5 is marketed by Esai Pharmaceutical Company and used to treat patients 
with metastatic breast cancer who have received at least two prior treatments in the EU,6 
U.S.7 and Japan.8 This compound binds to the plus end of microtubules and inhibits 
microtubule elongation but not shortening.9,10 Another microtubule dynamics inhibitor, 
noscapin, is undergoing a phase I/II clinical trial for multiple myeloma.3 These 
compounds have little effect on the microtubule network in interphase cells, but they 
induce abnormal spindle formation. Except for their interference with bipolar spindle 
formation, the effects of microtubule dynamics inhibitors on the cell functions have not 
been revealed. It is thus quite important to understand the functions of microtubule 
dynamics in cells to prevent the side effects induced by microtubule dynamics 
inhibitors.  
Glaziovianin A (AG1, Fig. 1), a new isoflavone isolated from the leaves of 
Brazilian pea Ateleia glazioviana, induces abnormal spindle formation (an abnormal 
alignment of chromosomes and multi-polar spindles) and arrests cell cycle progression 
of mammalian cells at M-phase.11 In a cancer cells panel screening performed by the 
Screening Committee for Anticancer Drugs (SCAD), AG1 showed similar score to 
those of microtubule polymerization inhibitors,11 suggesting that AG1 is a microtubule 
  
polymerization inhibitor. In previous studies, the effects of AG1 was investigated on the 
microtubules and it was revealed that AG1 delayed tubulin polymerization in vitro (Fig. 
2) and that the signals of EB1 (a microtubule plus end binding protein), which 
accumulates at growing microtubule plus ends,12, 13 disappeared soon after AG1 
treatment (Fig. 3). These data suggested that AG1 directly binds tubulin heterodimer 
and attenuated microtubule polymerization, and probably de-polymerization as well. 
However, the details of the effects of AG1 on microtubules and its inhibitory 
mechanisms remain to be revealed. In this thesis, therefore, I investigated the binding 
site of AG1 on tubulin heterodimer and AG1’s effect on microtubule dynamics in vitro 
and in vivo. 
To analyze the mode of action of small molecules, not only mammalian cells14,15 
but also a model organism such as yeast16,17 are often used. Mammalian cells are useful 
for analyses, such as observation of organelles using microscopy,14,15, biochemical 
experiments,15 because they are easy to observe their organelles morphology and to lyse 
the cells. In the field of chemical biology, mammalian cell’s high sensitivities against 
small compounds facilitates the analyses of mode of action. However, analyses of 
microtubule inhibitors are sometimes difficult because human cells have approximately 
eight α- and eight β-tubulin isoforms. Tubulins function as heterodimer, the number of 
  
the combination of α- and β-tubulin isoforms would thus be more than 60. In addition, 
several posttranslational modifications of microtubules, such as acetylation, 
phosphorylation, polyglutamylation and polyglycylation, have been reported.18 These 
complexity make analysis of microtubule inhibitors difficult.  
The budding yeast Saccharomyces cerevisiae, is also a useful tool for chemical 
biology studies because it is easy to use genetic analyses, mutational analyses,16 gene 
disruption, and genome modification14,17,19 (Fig. 4). S. cerevisiae has only two α-tubulin 
genes (TUB1 and TUB3) and one β-tubulin gene (TUB2), and TUB3 gene can be 
disrupted.20 S. cerevisiae can thus express single allele of α-/β-tubulin isoform (Tub1p 
and Tub2p) and genetic modifications of these genes are useful ways to analyze the 
mode of action of AG1 and other microtubule inhibitors.21 However, there is a major 
obstacle for mode of action analyses using S. cerevisiae. Budding yeast is resistant to 
most of the compounds to which mammalian cells are sensitive (Table 1). Therefore, 
new strains showing high sensitivities to AG1 are required for the analysis of the mode 
of action of AG1. 
In our laboratory, the molecular targets or binding sites of several bioactive 
compounds were determined using yeast genetics.14,16,17 To determine the target 
molecules and/or the binding site, it has been necessary to construct yeast strains 
  
suitable for the various compounds,16,22,23 but the construction of deletion strains that 
have sensitivities specific to each of the various compounds is a time-consuming 
process. Hence I speculated that the deletion of all of these genes (except those that are 
important for viability and genetic experiments) could increase the drug sensitivity 
without influencing transformation, mating, or sporulation efficiency. 
There are two factors conferring multidrug resistance in S. cerevisiae: one is the 
drug efflux system, and other is the permeability barrier. The drug efflux system is 
composed of ATP-binding cassette (ABC) transporters that export xenotoxic 
compounds to outside of cells or inside of vacuole24-26 and the transcriptional factors of 
ABC transporters.25,26 S. cerevisiae has at least 16 ABC transporters, of which Pdr5p, 
Snq2p and Yor1p confer multidrug resistance by exporting bioactive small molecules 
out of cells. And four transcriptional factors (Pdr1p, Pdr3p, Pdr8p and Yrr1p) 
up-regulate the transcription of most of the ABC transporters. In contrast, the major 
factor for the permeability barrier is ergosterol in the yeast plasma membrane. For these 
reasons, multidrug-sensitive strain lacking PDR1, PDR3 (transcriptional factors for 
ABC transporters) and ERG6 (ergosterol synthase) are used for drug screening.27 
However, this deletion mutant which lacks 3 genes (pdr1, pdr3, and erg6) decreases the 
transformation and sporulation efficiencies that are essential for yeast genetic analysis. I 
  
therefore hypothesized that it is possible to make highly multidrug-sensitive strain by 
the disruption of ABC transporters.  
In this thesis I focused on ABC transporters on only the plasma membrane 
(including Pdr5p, Snq2p and Yor1p) and their transcription factors. The constructed 
strain lacking eight ABC transporters and four transcription factors showed sensitivity 
against several compounds, but they were not sensitive to AG1 or AG1 derivatives. I 
therefore next introduced the ERG6 inducible expression system, and finally succeeded 
in constructing a strain showing sensitivity to AG1 derivative. 
  
  
Abstract 
In this thesis, I analyzed the effect of AG1 and the derivatives on the MT 
dynamics, and constructed multidrug hypersensitive yeast strain 12geneΔ0HSR-iERG6 
for investigation of the inhibitory mechanism of AG1.  
The MT dynamics analysis using EGFP-α-tubulin-expressing PtK2 cells 
revealed that AG1 decreases both of elongation and shortening velocities, and the 
frequency of catastrophes. These changes of parameter drastically increased the 
population of MT in pause phase, without depolymerization as described previously. 
Because it was revealed that AG1 inhibits MT dynamics of which the function is still 
unclear, therefore the function of MT dynamics was analyzed using AG1. My analysis 
revealed that AG1 inhibited EGF-stimulated EGFR transport without changing MT 
network. This data suggest that MT dynamics in cells regulate the endosome transport. 
These findings indicate that AG1 will be a useful tool to investigate the function of MT 
dynamics in cells. 
AG1 binds colchicine site on tubulin heterodimer, and it is expected that the 
analysis of the binding mode of AG1 in more detail will give new knowledge on the 
regulation of MT dynamics by inhibitors. However, human cells have several tubulin 
isoforms and posttranslational modifications of MTs, these complexity make 
  
biochemical analysis of MT inhibitors difficult. On the other hand, S. cerevisiae can 
express single allele of α-/β-tubulin isoform and genetic modifications of these genes 
are useful ways to analyze AG1. However, S. cerevisiae is resistant to most of the 
compounds including AG1, therefore multidrug-sensitive strain 12geneΔ0HSR-iERG6 
was constructed for analyzing the details of the mechanism of MT dynamics inhibition 
by AG1. 12geneΔ0HSR-iERG6 showed improved drug sensitivity to compounds 
including O7-propargyl AG1. Furthermore this strain showed sufficient transformation 
and sporulation efficiencies under the galactose condition, which are important property 
for genetic approach. The results suggest that 12geneΔ0HSR-iERG6 is useful tool to 
analyze not only O7-propargyl AG1 but also other small molecules using genetics 
approach.  
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